Skip to main content



Dr. Susmitha Vaka is board-certified in medical oncology, internal medicine, and hematology, and practices at our Riverside location. Originally from India, Dr. Vaka earned her Bachelor of Medicine and Surgery, and her Doctor of Medicine from Guntur Medical College in Guntur, India. She went on to complete her internship, residency, and fellowship training in hematology/oncology and breast oncology from the University of Kansas Medical Center.

Excited and motivated by her profession and the advancing field of technology, Dr. Vaka says: “It is my personal goal as a physician to provide the best and most advanced care and education for my patients.”

“When I meet new oncology patients, I start by understanding how they are feeling and what they know about the disease- stages of cancer, prognosis, and treatments. This allows be to better educate them so that I can involve them in the treatment plan with their goals and values in mind.”

Dr. Vaka was drawn to CSNF because of the cutting-edge treatments, clinical trials, and collaborative approach: “I enjoy the family environment that comes with working at CSNF,” she says. “It’s beyond rewarding, for our entire team, to watch patients live longer and spend more time with their loved ones,” she continues.

When not in the office, Dr. Vaka enjoys spending time with her family, cooking, traveling, and hiking.

Curriculum Vitae


Medical Oncology
Internal Medicine


American Society of Clinical Oncology
American Society of Hematology
American Medical Association


University of Kansas Medical Center
University of Kansas Medical Center
Breast Oncology


University of Kansas Medical Center


University of Kansas Medical Center


Guntur Medical College
Doctor of Medicine
Guntur Medical College
Bachelor in Medicine & Bachelor in Surgery

RESEARCH (Principal Investigator Responsibilities)

A Phase 2, Multi-Center, Randomized, Placebo Controlled, Double-Blind Study with LJPC-401 for the Treatment of Iron Overload in Adult Patients with Hereditary Hemochromatosis, Phase: II, Interventional
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (MYSTIC), Phase: III, Interventional
A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN), Phase: III, Interventional


Oncology Reviews
Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?